Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other long-term liabilities | 316 | 164 |
| Net cash used in operating activities | (12,913) | (52,929) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (9) | (99) |
| Proceeds from maturities of investments | 72,115 | 56,500 |
| Purchase of investments | (101,694) | (50,225) |
| Net cash provided by (used in) investing activities | (29,588) | 6,176 |
| Cash flows from financing activities: |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's capex?
- Allogene Therapeutics (ALLO) reported capex of $9K in Q1 2026.
- How has Allogene Therapeutics's capex changed year-over-year?
- Allogene Therapeutics's capex decreased by 90.9% year-over-year, from $99K to $9K.
- What is the long-term trend for Allogene Therapeutics's capex?
- Over 4 years (2021 to 2025), Allogene Therapeutics's capex has grown at a -63.4% compound annual growth rate (CAGR), from $21.45M to $386K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Allogene Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude